Innoviva delivered a strong third-quarter performance with total revenue reaching $107.8 million, a 20% increase year-over-year. This growth was fueled by resilient royalty revenue and a 52% year-over-year increase in U.S. net product sales. The company also reported a substantial net income of $89.9 million and launched ZEVTERA® in the U.S., while announcing a $125 million share repurchase program.
Total revenue for Q3 2025 increased by 20% year-over-year to $107.8 million.
U.S. net product sales grew by 52% year-over-year, reaching $29.9 million.
Net income for the quarter was $89.9 million, a significant increase from $1.2 million in the prior year.
Innoviva initiated a $125 million share repurchase program, reflecting confidence in its financial outlook.
Innoviva anticipates continued growth, particularly with the ongoing market receptivity for ZEVTERA® and the upcoming PDUFA date for zoliflodacin. The company plans to continue strategic capital deployment and share repurchases to enhance shareholder value.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance